Bright Minds is Unaware of Any Material Changes | Psychedelic Invest

NEW YORK, Sept. 12, 2024 /CNW/ – Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric disorders, today announced the initiation of the BREAKTHROUGH Study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101, a highly selective 5-HT2C receptor agonist, in adult patients with…

Two biotechs launch public offerings; Vaxxinity shares safety data on its Parkinson’s vaccine

Two biotechs are turning to public offerings to get more cash. California-based IGM Biosciences will be selling some of its stock. The biotech announced that

June 23, 2023

Bernie Sanders calls vote to subpoena Novo Nordisk U.S. head over Ozempic, Wegovy prices

WASHINGTON — Senate health committee chair Bernie Sanders has called a vote to subpoena the chief of Novo Nordisk’s U.S. division over the company’s pricing

June 11, 2024

How the brain keeps blood sugar levels in check

The body’s blood glucose level needs to be maintained in a relatively narrow range. It cannot be too high, as it can lead to diabetes,

July 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.